Janux Therapeutics
Clinical trials sponsored by Janux Therapeutics, explained in plain language.
-
New biologic drug JANX014 enters first human trial for tough prostate cancer
Disease control Recruiting nowThis early-stage trial is testing a new biologic drug, JANX014, in 43 men with metastatic castration-resistant prostate cancer that has progressed after other treatments. The main goal is to check safety and find the right dose, while also looking at how the drug moves through th…
Phase: PHASE1 • Sponsor: Janux Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for tough prostate cancer? early trial begins
Disease control Recruiting nowThis early-stage study tests a new drug called JANX007 in men with advanced prostate cancer that has spread and stopped responding to standard treatments. The main goal is to check safety and find the right dose. About 272 men will take part across multiple centers.
Phase: PHASE1 • Sponsor: Janux Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New autoimmune drug JANX011 enters first human safety trial
Knowledge-focused Recruiting nowThis early-stage study tests the safety of a new drug called JANX011 in 60 healthy adults. Researchers will give a single dose and monitor for side effects. The goal is to gather initial safety data before testing in people with autoimmune diseases.
Phase: EARLY_PHASE1 • Sponsor: Janux Therapeutics • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC